Equillium Inc
NASDAQ:EQ
Equillium Inc
Change in Working Capital
Equillium Inc
Change in Working Capital Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Change in Working Capital | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Equillium Inc
NASDAQ:EQ
|
Change in Working Capital
-$3.3m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Change in Working Capital
-$2.8B
|
CAGR 3-Years
-28%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
-13%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Change in Working Capital
-$880m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-5%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Change in Working Capital
$2.4B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
8%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Change in Working Capital
-$514.8m
|
CAGR 3-Years
-70%
|
CAGR 5-Years
-51%
|
CAGR 10-Years
-22%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Change in Working Capital
-$618.3m
|
CAGR 3-Years
31%
|
CAGR 5-Years
-25%
|
CAGR 10-Years
N/A
|
|
Equillium Inc
Glance View
Equillium, Inc. engages in the development of products for severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company is headquartered in La Jolla, California and currently employs 45 full-time employees. The company went IPO on 2018-10-12. The firm develops products to treat severe autoimmune and inflammatory disorders with unmet medical needs. The firm's initial product candidate, itolizumab (EQ001), is a clinical-stage, monoclonal antibody that selectively targets CD6, a co-stimulatory receptor differentially expressed on subsets of pro-inflammatory T cells. The firm's CD6 plays a central role in the modulation of effector T cell, or Teff cell, activity and trafficking. Activated Teff cells drive several immuno-inflammatory diseases across therapeutic areas including transplant science, systemic autoimmunity, pulmonary, neurologic, gastrointestinal, renal, vascular, ophthalmic and dermatologic disorders. The company also provides structured-domain peptides, including BNZ-1 and BNZ-2, entirely in-house from product discovery platform. These lead product candidates are multi-specific inhibitors that targets range of immuno-inflammatory indication.
See Also
What is Equillium Inc's Change in Working Capital?
Change in Working Capital
-3.3m
USD
Based on the financial report for Sep 30, 2024, Equillium Inc's Change in Working Capital amounts to -3.3m USD.
What is Equillium Inc's Change in Working Capital growth rate?
Change in Working Capital CAGR 1Y
-49%
Over the last year, the Change in Working Capital growth was -49%.
You don't have any saved screeners yet